Good morning. Elizabeth Cooney here writing from STAT’s Boston HQ, where we’re bracing for the heat wave that’s about to cook our edge of the East Coast. Ed Silverman is no doubt dreaming of weekend plans in between gathering intel in our nation’s capital. He’ll be back on the Pharmalot campus next week. Before I go, here’s a bookmark suggestion for you: STAT’s Drug Pricing Policy Tracker, a living list of developments curated by our Washington correspondents Nicholas Florko and Lev Facher. Enjoy.
Canada opposes any U.S. plans to buy Canadian prescription drugs that might threaten the country’s drug supply or raise costs for its own citizens, officials have told U.S. authorities, according to documents obtained by Reuters. That could be a new setback for the Trump administration and its efforts to tackle high drug prices, as well as for U.S. lawmakers who have argued they can lower skyrocketing prescription drug prices by approving lower-priced imports from Canada. At least 10 U.S. states have passed or proposed laws to allow such imports, but actual shipments require federal approval to be legal.
About the Author Reprints
Concerning the Vanda item, instead of too little clinical data, it seems one company is offering “a boatload?”